- Company
- Takeda’s colorectal cancer drug 'Fruzaqla' nears KOR entry
- by Eo, Yun-Ho Mar 26, 2024 06:30am
- New colorectal cancer drug 'Fruzaqla' is likely to receive approval for commercialization in South Korea. According to industry sources on the 11th, Takeda Pharmaceuticals Korea’s Fruzaqla (fruquintinib), designated as Global Innovative products on Fast Track (GIFT) by the Ministry of Food and Drug Safety (MFDS), is under review for app
- Company
- K-bio, R&D global competitiveness will be put to the test
- by Son, Hyung-Min Mar 22, 2024 06:09am
- The Korean pharmaceutical industry will showcase its new candidate products entering late-stage clinical trials or aiming to export technology on platforms, testing their global competitiveness. The spotlight is on these new candidate products, particularly the trending bispecific antibodies and antibody-drug conjugate (ADC), to identify w
- Company
- Lotte Biologics’ sales amount to KRW 228.6 billion
- by Kim, Jin-Gu Mar 22, 2024 06:09am
- Lotte Biologics recorded sales of KRW 228.6 billion last year. As the Syracuse manufacturing plant in the United States went into full-scale production, sales of KRW 83.1 billion in the first half of the year expanded to KRW 145.6 billion in the second half of the year. The analysis indicates that Lotte Biologics’ Contract development
- Company
- Antihistamine sales benefit from end of pandemic and endemic
- by Son, Hyung-Min Mar 22, 2024 06:06am
- Last year, sales of major antihistamines showed a clear recovery, exceeding the level it had made before the pandemic. Sales of antihistamines had plummeted in 2020 and 2021 during the COVID-19 pandemic. The analysis is that the increase in sales is likely due to the rise in allergy patients with the lifted mask mandates and the increase in outd
- Company
- Luxturna prescriptions available for rare retinal disease
- by Eo, Yun-Ho Mar 22, 2024 06:06am
- Prescriptions for the gene therapy ‘Luxturna,’ which targets only a few patients, are becoming available in South Korea. According to industry sources, Novartis Korea’s Luxturna (voretigene neparvovec), a therapy used to treat inherited retinal dystrophy (IRD), has cleared the Drug Committee (DC) of the tertiary general hospitals, in
- Company
- "Envlo shows superior effects in diabetic kidney disease"
- by Son, Hyung-Min Mar 21, 2024 05:52am
- Daewoong Pharmaceutical announced on the 19th that Envlo (ingredient: enavogliflozin), an SGLT-2 class diabetes treatment from the company’s drug discovery, demonstrated superior effects in patients with diabetes compared to dapagliflozin. Based on the clinical results, Envlo has shown superior effects in all four indexes, including ▲
- Company
- Haleon Korea declares full independence from GSK
- by Eo, Yun-Ho Mar 21, 2024 05:52am
- The consumer healthcare company Haleon has declared its full independence from GSK. Haleon Korea, the Korean subsidiary of Haleon, announced on the 20th that it has completed the official registration of its business and is embarking on a new journey. The company had been completely spun off from GSK in July 2022 to become a 100% consu
- Company
- Fintepla gets orphan drug designation for Dravet syndrome
- by Eo, Yun-Ho Mar 21, 2024 05:52am
- 'Fintepla' has been designated as an orphan drug in South Korea for its indication for Dravet syndrome. The Ministry of Food and Drug Safety (MFDS) has announced this in the posting of the Orphan Drug Designation. UCB’s Fintepla (fenfluramine) initially acquired FDA approval for the treatment of rare epilepsy of infancy in 2020. Addit
- Company
- SK Life Science’s sales rise tenfold in 5 years in the US
- by Chon, Seung-Hyun Mar 20, 2024 05:44am
- SK Biopharmaceuticals' U.S.-based subsidiary posted sales of nearly KRW 500 billion last year. The sales of its epilepsy drug cenobamate increased in the U.S., increasing the company’s sales by over tenfold in 5 years. According to the Financial Supervisory Service on Tuesday, SK Life Science’s sales totaled KRW 49.9 billion last year, up
- Company
- Sales of Tagrisso stay strong, Leclaza rises in lung cancer
- by Mar 20, 2024 05:44am
- In the EGFR-positive non-small cell lung cancer (NSCLC) treatment market, Leclaza’s sales growth stood out amid strong sales of Tagrisso. Tagrisso and Leclaza are both third-generation targeted therapies, and the two were approved as a first-line treatment for lung cancer this year and were given the green light to expand sales. Among firs
